CNS Pharmaceuticals (CNSP) Competitors $0.10 -0.01 (-8.44%) (As of 12:49 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CNSP vs. ADMP, PULM, CPIX, TXMD, NERV, SLGL, SYBX, GOVX, HCWB, and IPAShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Adamis Pharmaceuticals (ADMP), Pulmatrix (PULM), Cumberland Pharmaceuticals (CPIX), TherapeuticsMD (TXMD), Minerva Neurosciences (NERV), Sol-Gel Technologies (SLGL), Synlogic (SYBX), GeoVax Labs (GOVX), HCW Biologics (HCWB), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "medical" sector. CNS Pharmaceuticals vs. Adamis Pharmaceuticals Pulmatrix Cumberland Pharmaceuticals TherapeuticsMD Minerva Neurosciences Sol-Gel Technologies Synlogic GeoVax Labs HCW Biologics ImmunoPrecise Antibodies Adamis Pharmaceuticals (NASDAQ:ADMP) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation. Does the MarketBeat Community prefer ADMP or CNSP? Adamis Pharmaceuticals received 287 more outperform votes than CNS Pharmaceuticals when rated by MarketBeat users. However, 71.21% of users gave CNS Pharmaceuticals an outperform vote while only 59.96% of users gave Adamis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAdamis PharmaceuticalsOutperform Votes33459.96% Underperform Votes22340.04% CNS PharmaceuticalsOutperform Votes4771.21% Underperform Votes1928.79% Do analysts prefer ADMP or CNSP? CNS Pharmaceuticals has a consensus price target of $0.50, suggesting a potential upside of 371.70%. Given CNS Pharmaceuticals' higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Adamis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adamis Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ACNS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ADMP or CNSP? Adamis Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.58, suggesting that its share price is 158% more volatile than the S&P 500. Is ADMP or CNSP more profitable? CNS Pharmaceuticals has a net margin of 0.00% compared to Adamis Pharmaceuticals' net margin of -502.73%. CNS Pharmaceuticals' return on equity of 0.00% beat Adamis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Adamis Pharmaceuticals-502.73% -420.53% -256.87% CNS Pharmaceuticals N/A N/A -783.14% Do institutionals and insiders believe in ADMP or CNSP? 38.6% of Adamis Pharmaceuticals shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 1.3% of Adamis Pharmaceuticals shares are held by company insiders. Comparatively, 9.2% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to ADMP or CNSP? In the previous week, Adamis Pharmaceuticals' average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score. Company Overall Sentiment Adamis Pharmaceuticals Neutral CNS Pharmaceuticals Neutral Which has higher earnings & valuation, ADMP or CNSP? CNS Pharmaceuticals has lower revenue, but higher earnings than Adamis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdamis Pharmaceuticals$4.76M0.00-$26.48MN/AN/ACNS PharmaceuticalsN/AN/A-$18.85M-$128.720.00 SummaryCNS Pharmaceuticals beats Adamis Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Ad Golden CrestCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.45M$6.75B$5.02B$8.42BDividend YieldN/A7.94%7.49%4.16%P/E Ratio0.0011.78128.4816.64Price / SalesN/A288.471,723.1677.30Price / CashN/A46.0936.9033.53Price / Book0.005.284.595.19Net Income-$18.85M$150.82M$113.94M$223.67M7 Day Performance-28.90%-0.69%110.64%2.76%1 Month Performance-13.72%15.56%124.65%8.82%1 Year Performance-99.90%37.06%155.07%29.33% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals1.2821 of 5 stars$0.10-8.4%$0.50+385.0%-99.9%$3.45MN/A0.005Gap DownADMPAdamis PharmaceuticalsN/AN/AN/AN/A$7.26M$4.76M0.0011Gap DownPULMPulmatrix0.1853 of 5 stars$2.14+2.4%N/A+11.5%$7.82M$11.39M-0.7220Analyst ForecastNews CoverageCPIXCumberland Pharmaceuticals0.5613 of 5 stars$1.24-0.8%N/A-44.6%$17.60M$37.79M-1.7080Upcoming EarningsAnalyst ForecastTXMDTherapeuticsMD0.8165 of 5 stars$1.57+0.6%N/A-29.9%$18.11M$996,000.000.00420Analyst ForecastNews CoverageNERVMinerva Neurosciences4.0475 of 5 stars$2.54+3.2%$5.00+96.5%-52.5%$17.79MN/A-0.579Upcoming EarningsAnalyst ForecastGap DownSLGLSol-Gel Technologies2.4441 of 5 stars$0.62-4.7%$5.00+713.0%-61.4%$17.13M$6.56M-1.1450Gap UpSYBXSynlogic2.7739 of 5 stars$1.46+2.8%$30.00+1,954.8%-21.5%$17.09M$3.17M-0.2280Positive NewsGOVXGeoVax Labs3.2114 of 5 stars$2.01+1.0%$12.67+530.2%-75.7%$16.86M$300,677.000.0017HCWBHCW Biologics0.4949 of 5 stars$0.44-2.2%N/A-73.1%$16.68M$3.92M-0.4240Gap UpIPAImmunoPrecise Antibodies2.55 of 5 stars$0.54-5.2%$6.00+1,008.0%-75.7%$16.60M$24.09M-0.6980News CoverageHigh Trading Volume Related Companies and Tools Related Companies ADMP Competitors PULM Competitors CPIX Competitors TXMD Competitors NERV Competitors SLGL Competitors SYBX Competitors GOVX Competitors HCWB Competitors IPA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNSP) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
